EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report

Antonino Marcello Pilia, Lorenzo Salvati, Alessia Guidolin, Francesca Mazzoni, Lorenzo Antonuzzo, Paola Parronchi, Francesco Liotta

Swiss Medical Weekly · 2024

DOI: 10.57187/s.3513 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Swiss Medical Weekly, 2024. Verfasst von Antonino Marcello Pilia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatomyositis, Lung Diseases, Interstitial, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report the first case of anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis as a systemic immune-related adverse event in a 64-year-old man receiving pembrolizumab to treat advanced lung cancer. The patient experienced hypothyroidism, myalgia, skin involvement, dyspnoea and diarrhoea. Laboratory tests revealed raised inflammatory markers, hypercreatinekinasemia and anti-MDA5 autoantibodies. Electroneuromyography and pathognomonic signs on physical examination confirmed the diagnosis of pauci-myopathic dermatomyositis. Pembrolizumab was discontinued and immunosuppressive therapy led to rapid and progressive improvement, with complete remission of dermatomyositis. This case report widens the spectrum of systemic immune-related adverse events associated with pembrolizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDermatomyositisLung Diseases, InterstitialLung NeoplasmsHumansMaleMiddle AgedAutoantibodiesInterferon-Induced Helicase, IFIH1

Substanzen

Antibodies, Monoclonal, HumanizedAutoantibodiesInterferon-Induced Helicase, IFIH1pembrolizumabIFIH1 protein, human

Autor:innen und Institutionen

  • Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Clinical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Medical Oncology, Careggi University Hospital, Florence, Italy.
  • Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy.

Zitieren

APA

Pilia, A. M., Salvati, L., Guidolin, A., Mazzoni, F., Antonuzzo, L., Parronchi, P., & Liotta, F. (2024). Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report. Swiss Medical Weekly. https://doi.org/10.57187/s.3513

Vancouver

Pilia AM, Salvati L, Guidolin A, Mazzoni F, Antonuzzo L, Parronchi P, et al. Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report. Swiss Medical Weekly. 2024. doi:10.57187/s.3513

BibTeX
@article{Pilia2024,
  author = {Pilia, Antonino Marcello and Salvati, Lorenzo and Guidolin, Alessia and Mazzoni, Francesca and Antonuzzo, Lorenzo and Parronchi, Paola and Liotta, Francesco},
  title = {Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report},
  journal = {Swiss Medical Weekly},
  year = {2024},
  doi = {10.57187/s.3513}
}
Kostenlos starten →